ReviewAuto- immunity highlights2020
The perspective on standardisation and harmonisation: the viewpoint of the EASI president.
Review in Auto- immunity highlights, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis.Journal of translational autoimmunity · 2026Review
- Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Autoantibodies as prognostic markers in rheumatoid arthritis.Journal of translational autoimmunity · 2025Review
- Antineutrophil Cytoplasmic Antibodies (ANCAs): Role in Diagnosis, Disease Monitoring, and Prognosis.Journal of the American Society of Nephrology : JASN · 2025Review
- Atypical Hemolytic Uremic Syndrome: A Review of Complement Dysregulation, Genetic Susceptibility and Multiorgan Involvement.Journal of clinical medicine · 2025Review
- Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays.Antibodies (Basel, Switzerland) · 2024Article
- Autoantibodies to dsDNA in the diagnosis, classification and follow-up of patients with systemic lupus erythematosus.Journal of translational autoimmunity · 2023Article
- Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up.Journal of translational autoimmunity · 2022Article
- Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus.Journal of translational autoimmunity · 2022Article
- Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application.Journal of translational autoimmunity · 2022Article
- Autoantibodies in the criteria of autoimmune diseases: is it sufficient to know that the test is positive?Journal of translational autoimmunity · 2022Article
- Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine.Biochemia medica · 2021Review
- The antinuclear antibody HEp-2 indirect immunofluorescence assay: a survey of laboratory performance, pattern recognition and interpretation.Auto- immunity highlights · 2021Article
- Likelihood Ratio Approach and Clinical Interpretation of Laboratory Tests.Frontiers in immunology · 2021Article
- ANCA Testing in Clinical Practice: From Implementation to Quality Control and Harmonization.Frontiers in immunology · 2021Review
- Standardization and Quality Assessment Under the Perspective of Automated Computer-Assisted HEp-2 Immunofluorescence Assay Systems.Frontiers in immunology · 2021Review
- The clinical and the laboratory autoimmunologist: Where do we stand?Auto- immunity highlights · 2020Article
- Hellenic Association for the Study of the Liver (HASL): revised clinical practice guidelines for autoimmune hepatitis.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standardisation of immuno-assays for autoantibodies is a major challenge. Although multiple organisations participate in the generation of internationally accepted standards, adequate standardisation of assays has not yet been achieved. Harmonisation may offer an alternative approach to better align requesting, testing, reporting and interpretation of autoimmune diagnostics. The European Autoimmunity Standardisation Initiative (EASI) was founded to facilitate both standardisation as well as harmonisation of autoantibody tests, but over the years the focus has drifted away from standardisation in favour of harmonisation. In the current paper the options for harmonisation are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.